

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 63/00, C12N 5/00	A1	(11) International Publication Number: WO 97/46104 (43) International Publication Date: 11 December 1997 (11.12.97)
(21) International Application Number: PCT/US97/09626 (22) International Filing Date: 3 June 1997 (03.06.97) (30) Priority Data: 08/658,473 5 June 1996 (05.06.96) US (71) Applicant: BIOGAIA BIOLOGICS AB [SE/SE]; P.O. Box 23128, S-104 35 Stockholm (SE). (71)(72) Applicants and Inventors: CASAS, Ivan, A. [US/US]; 4916 North Hills Drive, Raleigh, NC 27612 (US). MOLL-STAM, Bo [SE/SE]; Suite D, 6213 Angus Drive, Raleigh, NC 27613 (US). (74) Agent: BARBER, Lynn, E.; P.O. Box 6450, Raleigh, NC 27628 (US).		(81) Designated States: AU, BR, CA, EE, IL, JP, KR, MX, NO, NZ, PL, RU, SG, YU, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <i>With an indication in relation to a deposited microorganism furnished under Rule 13^{bis} separately from the description.</i> <i>Date of receipt by the International Bureau:</i> 1 July 1997 (01.07.97)
(54) Title: TREATMENT OF DIARRHEA (57) Abstract A therapeutic method of treating diarrhea of a patient, such as that caused by rotavirus in which a liquid suspension of one or more strains of <i>Lactobacillus reuteri</i> is administered to the patient. Preferably the <i>L. reuteri</i> is isolated from an animal of the same species as the animal to which the therapy is being given. Preferably at least about 10 ⁷ cells of <i>L. reuteri</i> , and most preferably, at least 10 ⁸ cells, are administered per day, over a period of one to seven days, depending on the severity of the gastroenteritis. The result is rapid, dramatic reduction in animal's diarrhea and vomiting, previously not found using other therapies.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

"TREATMENT OF DIARRHEA"

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to therapeutic treatment of infectious gastroenteritis.

5 Description of the Related Art

Normal microflora is important in the protection of the host against diseases of the gastrointestinal (GI) tract (Fuller, R., *Gut* 1991;32:439-42; Salminen, S. et al., *Dig Dis Sci* 1992;10:227-38). During periods of acute diarrhea, the normal gastrointestinal microflora is radically changed. These changes include decreasing numbers of
10 *Lactobacilli*, *Bacteroides* and *Bifidobacteria* (Salminen S. et al., *Dig Dis Sci* 1992;10:227-38; Tazume S. et al., *Clin Infect Dis* 1993;16(2 suppl):77-82S; Mitsuoka T., in Wood BJB, London:Elsevier Applied Science 1992, 1:69-114; Salminen S. et al., *Chemotherapy*, in press.).

Lactobacillus reuteri is the most commonly occurring *Lactobacillus* species found
15 in the GI tract of humans and animals (Kandler O. et al., *Zbl Bakt Abt Orig* 1980; C1:264-9). Like other *Lactobacilli*, *L. reuteri* produces acidic metabolic end-products (lactic and acetic acids) which have considerable antimicrobial activity (Axelson L.T. et al., *Microb Ecology Health Dis* 1989;2:131-6). Use of *L. reuteri* cell therapy for other than probiotic purposes, i.e., benefitting the host by improving the indigenous
20 microflora, or antibiotic purposes, is not known.

Several studies have indicated that the administration of probiotic agents may modulate the microbial balance of the host and attenuate acute periods of diarrhea (Pearce J.L. et al., *J. Pediatr* 1974;84:261-2; Brunser O. et al., *Acta Paediatrica Scand* 1989;78:259-64; Boudraa G. et al., *J Pediatr Gastroenterol Nutr* 1990;11:509-12).
25 *Lactobacillus casei* strain GG (LcGG) has been shown to promote clinical recovery from rotavirus gastroenteritis in children and enhance intestinal immune responses (Isolauri E. et al., *Pediatrics* 1991;88:90-7; Kaila M. et al., *Int Pediatr Research Foundation, Inc.* 1992;32:141-4; Majamaa H. et al., *J Pediatr Gastroenterol Nutr* 1995;20:333-8). Other commercially available preparations of lactic acid bacteria, such as, *L. casei* subsp.
30 *rhamnosus* (*Lactophilus*), *L. delbrückii* subsp. *bulgaricus* and others are also being used for the treatment of acute diarrhea, even though their efficacy has not been formally demonstrated (Majamaa H. et al., *J Pediatr Gastroenterol Nutr* 1995;20:333-8). *L.*

reuteri has been shown to be safe on exogenous administration to healthy humans (Wolf B.W. et al., *Micro Ecology Health Dis* 1995;8:41-50) and has shown therapeutic potential in a rat model of colitis (Fabia R. et al., *Scand J Gastroenterol* 1993;28:155-62).

- 5 *L. reuteri* is known to produce a broad spectrum antimicrobial, called reuterin (Axelson L.T. et al., *Microb Ecology Health Dis* 1989;2:131-6), which may be responsible for inhibition of pathogenic microorganisms in the gastrointestinal tract.

SUMMARY OF THE INVENTION

10 The invention herein is a method for treatment of diarrhea utilizing one or more strains of *Lactobacillus reuteri* isolated from an animal of the same species as the animal to which the therapy is being given. Preferably at least about 10^7 cells of *L. reuteri* are administered over a period of at least one day, depending on the severity of the gastroenteritis. The result is a rapid, dramatic reduction in the animal's diarrhea and vomiting, previously not found using other therapies.

- 15 It is an object of this invention to provide a method of treating acute diarrhea that is more effective and faster in stopping dehydration of young patients than earlier methods.

Other aspects, features and objects of the invention will be more fully apparent from the following disclosure and appended claims.

20 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 graphically shows the frequency of watery stools per 24 hour period in patents receiving *L. reuteri* or a placebo, presented as absolute number of diarrheal stools (Figure 1a) and percentage reduction compared to admission level (Figure 1b). The solid squares indicate the *L. reuteri* treatment and the open squares show the placebo.

- 25 Figure 2 shows the frequency of vomiting per 24 hour period in patients receiving *L. reuteri* or a placebo, presented as absolute number of vomiting episodes (Figure 2a) and percent reduction from the admission level (Figure 2b). The solid squares indicate the *L. reuteri* treatment and the open squares show the placebo.

30 Figure 3 shows the total fecal lactobacillus in the placebo (the second block of each pair of blocks) and in *L. reuteri* - fed children (the first block in each pair of blocks).

Figure 4 shows the fecal *L. reuteri* count in the placebo (the second block of each pair of blocks) and in *L. reuteri* - fed children (the first block in each pair of blocks).

Figure 5 shows the *L. reuteri* as a percent of the total fecal Lactobacillus population in the placebo (second block of each pair of blocks) and in *L. reuteri* - fed children (first block of each pair of blocks).

DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS THEREOF

The invention herein is a method of providing therapy to a mammal having diarrhea, comprising determining that the mammal has diarrhea or is imminently susceptible to diarrhea; selecting a strain of *Lactobacillus reuteri*; preparing at least one aliquot of cells of the strain containing about 10^7 - 10^{10} , preferably at least about 10^8 , cells for administration to the mammal; and orally administering the at least one aliquot to the mammal as soon as possible after diagnosis of diarrhea. The aliquots may be lyophilized cells, which are suspended in a liquid for administration to the mammal. The liquid may be water, fruit juices, dairy products such as milk or yogurt, and the like, which are not harmful to the mammal. The lyophilized cells may be packaged in a moisture impermeable package, such as a foil package, or in a gelatin capsule as is known. As an alternative to liquid administration to the mammal, the lyophilized cells may be placed in a gelatin capsule for administration to the mammal. Preferably the strain of *Lactobacillus reuteri* is one that has been isolated from the same type of mammal to which the therapy is being provided. The invention further comprises a therapeutic preparation for reduction of diarrhea symptoms, comprising at least about 10^7 viable cells of a strain of *L. reuteri* in an aliquot for administration to a mammal.

The present invention provides a method of treating acute diarrhea in humans, comprising administering *Lactobacillus reuteri*. Preferably, treatments extend over a period of at least one to seven days, preferably begun as soon as possible after diagnosis of diarrhea, with a level of 10^7 - 10^{10} cells administered per day. The sooner the treatment begins, the sooner the administered *L. reuteri* cell therapy can eliminate the diarrhea.

In summary of the main study reported herein, to determine the effect of a human *Lactobacillus* strain (*Lactobacillus reuteri* strain SD 2112) on recovery from acute diarrhea (75% rotavirus), 40 patients between 6 and 36 months of age were studied.

This strain of *L. reuteri* has been deposited with the American Type Culture Collection as ATCC No. 55730, under the Budapest Treaty on December 7, 1995, and was originally isolated from human breast milk.

After parental consent, the patients were randomized to one of two groups, and
5 received either 10^{10} to 10^{11} cfu of *L. reuteri* SD 2112 or a matching placebo daily for the length of hospitalization or up to 5 days. Treatments were administered in 50 to 100 ml of liquid. The mean (SD) duration of watery diarrhea after commencing the therapy in *L. reuteri* group was 1.7 [1.6] days and in placebo group 2.9 [2.3] days ($p=0.07$). On
10 the second day of treatment only 26% of patients receiving *L. reuteri* had watery diarrhea, as compared with 81% of those receiving the placebo ($p=0.0005$). Cultures of lactobacilli from stool samples demonstrated that administration of *L. reuteri* accounted for more than 75% of the total lactobacilli found in children fed with this product. It is concluded that *L. reuteri* is effective as a therapeutic agent in acute diarrhea in children.

15 Clinical results, substantiated by faecal analysis, indicate that the colonization of *L. reuteri* in the GI tract resulted in shortening and amelioration of acute diarrhea, mainly of rotavirus etiology. The benefits of *L. reuteri* therapy were observed within 24 hours after treatment started, after which a reduction of watery diarrhea was seen in most patients. The observation that 74% of the treated patients and only 19% of placebo
20 patients were diarrhea free on the second of therapy is clearly of clinical significance. This result compares favorably with the previous experience of *Lactobacillus GG* (Isolauri E. et al., *Pediatrics* 1991;88:90-7; Majamaa H. et al., *J Pediatr Gastroenterol Nutr* 1995;20:333-8), which in turn was found clinically more effective than a combination *Streptococcus thermophilus* and *L. delbrückii* subsp. *Bulgaricus* (Yalacta)
25 and *L. casei* subsp. *Rhamnosus* (Lactophilus) in the treatment of acute diarrhea. The present results may be further improved by earlier administration of *L. reuteri*. In the main study reported herein, *L. reuteri* therapy was started at a relatively late stage of diarrhea in patients requiring hospitalization, and even so only after rehydration and securing of parental consent. In many instances the delay was considerable.

30 The clinical results were corroborated by the bacteriological findings, which indicated a low total number of lactobacilli and virtual absence of *L. reuteri* in the placebo recipients, and high total lactobacilli and colonization of *L. reuteri* in the

treatment group. The colonization data suggests that the presence of *L. reuteri* in the GI tract may improve gut ecology by facilitating the growth of other beneficial microorganisms (Fuller R., *Gut* 1991;32:439-42).

The features and advantages of the present invention will be more clearly understood by reference to the following examples, which are not to be construed as limiting the invention.

EXAMPLES

Patients Studied

The study was carried out between January 29 and July 3, 1995, corresponding to a rotavirus epidemic season. The study protocol had been approved by the Ethical Review Committee of Tampere University Hospital, Tampere, Finland. This was a randomized, double-blind study. Study subjects included 41 well-nourished patients (61% male) between 6 and 36 months of age consecutively admitted to the Department of Paediatrics, Tampere University Hospital, for acute diarrhea of less than 7 days' duration and with more than one watery stool during the previous 24 hours. Children were enrolled in or excluded from the study based on the following inclusion and exclusion criteria. Patients were eligible for study if they were 6 to 36 months of age, admitted for acute diarrhea, had a history of ingesting bovine dairy products (milk, yogurt, infant formula, etc.) as part of their normal diet, and had a parent or legal guardian who signed an informed consent. Patients were excluded from study if they were taking immunosuppressive therapy or suffering from immune deficiency, had a history of allergy to bovine milk, had a serious underlying disease, had taken an investigational product during the preceding month, or had a parent or legal guardian who refused to sign an informed consent.

A randomization schedule was prepared to assign approximately 50% of enrolled patients to each treatment group (*L. reuteri* and placebo). Randomization numbers were sequentially assigned to patients as they were enrolled in the study.

Pre-Study Data Collection

At the time of admission, the children were weighed, clinically examined, and the severity of dehydration was estimated. Acute weight loss was calculated as the difference between expected weight (according to individual growth charts) and observed weight. Fluid deficit (dehydration percent) was then defined from the clinical signs of

dehydration and acute weight loss with a reduction of 0.5 to 1 % per day of diarrhea had continued for at least 3 days to reflect loss of weight due to low caloric intake. Serum levels of sodium and potassium as well as the blood acid-base balance were determined from a blood specimen collected on admission.

5 Treatment

After admission to the hospital, the patients were managed according to a standard treatment practice, first with oral rehydration followed by rapid resumption of full feeding (Isolauri E. et al., *J Pediatr Gastroenterol Nutr* 1985;4 366-74), but without antidiarrheal drugs. Oral rehydration was accomplished in 6 hours with a solution
10 containing Na⁺ (60 mmol/l) and glucose (84 mmol/l), given at two times the fluid deficit, with a minimum of 30 ml/kg (Rautanen T. et al., *Acta Paediatr* 1993;82:52-4).

Patients were equally randomized to one of two groups. Group 1 (n=19) received 10¹⁰ to 10¹¹ cfu of *L. reuteri* SD 2112 once a day. Group 2 (n=21) received a matching placebo once a day. The placebo consisted of nonfat dry milk powder. *L.*
15 *reuteri* and placebo formulations were prepared, quality controlled, and quality assured by BioGaia Biologics, Inc. (Raleigh, North Carolina, USA) prior to shipping. Each one-gram (10¹⁰ to 10¹¹ cfu/g) dose of *L. reuteri* was packaged in freeze-dried form in sterile sealed plastic vials using nonfat dry milk powder as a carrier. One gram freeze-dried preparations of *L. reuteri* or the placebo were reconstituted in 50 to 100 ml of a fluid of
20 choice. Hot food was tempered before mixing with the formulations. The feeding of the assigned preparation was started immediately after the informed consent had been obtained. The patients received *L. reuteri* or placebo for 5 days or for the duration of hospitalization, if shorter.

The patients were weighed daily in the ward. The number and the quality of the
25 stools and vomitus were followed by attending nurses. The stools were recorded as watery, loose or solid. The duration of diarrhea was counted from the last appearance of watery stools. The duration of diarrhea was calculated as decimal days. The patients were discharged according to the clinical judgment of the attending physician. They were asked to contact the investigators if diarrhea recurred in follow-up period of 1
30 month, at which point they were seen again for the collection of a blood specimen.

Patient Data Collection

Concentrations of serum sodium, potassium, and blood acid-base analysis were determined in the Hospital laboratory using standard procedures.

Rotavirus antigen was demonstrated using a commercial enzyme-immunoassay (Dakopatts AS, Denmark) in the Department of Virology, Medical School, University of Tampere. Blood specimens for rotavirus serology were collected the same day or one day after admission and four weeks later for the determination of rotavirus antibodies. Rotavirus IgA class antibodies were determined using an ELISA method (Isolauri E. et al., *Vaccine* 1995;13:310-2).

Stools were collected from each subject for analysis of total lactobacilli and *L. reuteri*. Fecal samples were collected at baseline prior to study product administration, 48 hours after study product administration and at hospital discharge. No less than 2 g of stools were collected for microbial analysis. The samples were homogenized and diluted in 0.1% peptone water for final ratio of 1:5. Five aliquots of 1.6 ml each of well mixed preparations were quick frozen and stored at -70°C. Diluted stool samples were sent to BioGaia Biologics, Inc., Raleigh, NC USA, for the determination of the total faecal lactobacilli and *L. reuteri*.

Faecal activities of the enzymes urease, β -glucuronidase and β -glucosidase were determined in the laboratory of Clinical Nutrition Department of University of Kuopio as previously described (Ling W.H. et al., *Ann Nutr Metab* 1992;36:162-6).

20 Statistical Methods

Statistical analysis was performed using Student's t-test and analysis of variance (Anova) to determine statistical differences between study groups. When comparing repeated measurements, the paired t-test and Anova for repeated measures were applied.

25 Results

Forty-one patients were initially enrolled in the study. One child in the placebo group was removed from the analysis, because *L. reuteri* was found in the stool samples. His sister, also included in the trial, was assigned to the *L. reuteri* group. It was obvious that cross contamination had taken place between these children. Of the remaining 40 children, 19 and 21 patients were assigned to the *L. reuteri* and placebo treatments, respectively. Thirty (75%) patients had rotavirus antigen in the stool specimens by

enzyme-immunoassay. Rotavirus was found in the *L. reuteri* group from 12 (63%) patients and in the placebo group from 18 (86%) patients.

The pertinent clinical characteristics of the total study group (n=40) are presented in Table 1:

Clinical Characteristics of Children Hospitalized for Acute Diarrhea and Enrolled in Study			
Clinical Evaluation	Mean \pm	SD	Range
Age (months)	16.5	8.8	6 to 36
Duration of diarrhea before treatment (days)	3.0	1.7	1 to 7
10 Dehydration (%)	3.4	1.4	0 to 7
Acute weight loss (g)	371	188	150 to 891
<u>Serum</u> Na ⁺ (mmol/L)	138	3.1	130 to 144
<u>Blood</u> 15 pH, actual	7.35	0.06	7.24 to 7.46
Base excess (mmol/L)	-7.1	4.4	-15 to +2.3

The mean (SD) duration of diarrhea until treatment was 3.0 (1.7) days. On admission most patients had mild dehydration, mean 3.4 (1.4)%. The serum sodium was between 130 and 144 mmol/L, with a mean of 138 mmol/l. The rotavirus-positive patients had 20 diarrhea for 2.6 (1.5) days at home as compared to 3.1 (1.9) days in rotavirus-negative patients (difference not significant). The degree of dehydration in rotavirus-positive children was not significantly more severe than in rotavirus-negative patients, but they had more metabolic acidosis (base deficit 7.8 (4.3) mmol/l) than the non-rotavirus patients on admission (mean base deficit 4.8 (3.8) mmol/l), respectively (p=0.07).

25 The characteristics of patients receiving *L. reuteri* or placebo are presented in Table 2. On admission, the groups were comparable except that in the *L. reuteri* group

the children were more dehydrated than in the placebo group. Weight gain after rehydration was similar in the two groups, as was correction of the metabolic acidosis.

Table 2

Clinical Characteristics on Admission of Patients
Receiving *L. reuteri* or Placebo

5

Clinical Evaluation	<i>L. reuteri</i> n=19		Placebo n=21		P
	Mean	± SD	Mean	± SD	
Age (months)	16.8	8.1	16.3	9.5	0.86
Acute weight loss (g)	415	190	328	181	0.15
Dehydration (%)	3.9	1.3	3.0	1.2	0.025
10 Duration of diarrhea before treatment (days)	3.1	1.7	2.8	1.8	0.66
<u>Blood</u> pH, actual	7.36	0.06	7.36	0.06	0.96
Base excess (mmol/L)	-7.6	4.4	-6.6	4.4	0.50
15 <u>Serum</u> Na ⁺ (mmol/L)	138	3.1	139	3.2	0.56

The clinical outcome of the two treatments was similar for weight gain, correction of acidosis and electrolyte levels (Table 3).

Table 3Clinical Outcome of Patients Receiving *L. reuteri* or Placebo

	Clinical Evaluation	<i>L. reuteri</i> n=19	Group 19	Placebo n=21	Group	P
		Mean \pm	SD	Mean \pm	SD	
5	Weight gain at rehydration	188	270	122	145	0.40
	Weight gain at discharge	-4.4	293	-4.7	166	0.99
	Duration of diarrhea in hospital (days)	1.7	1.6	2.9	2.3	0.07
10	<u>Blood</u>	7.38	0.04	7.39	0.03	0.49
	pH, after rehydration					
	Base excess (mmol/L) after rehydration	-2.7	3.3	-3.3	2.8	0.59
15	Base excess at discharge	-0.6	2.5	-1.6	3.4	0.44
	<u>Serum</u>					
	Na ⁺ (mmol/L)					
	after rehydration	139	2.0	138	2.9	0.56
	at discharge	139	1.9	139	3.0	0.63

The duration of watery diarrhea was shorter in the *L. reuteri* (p=0.07). Days 0, 1, 2, 3, 4, 5 and 6 were calculated as 24 hour periods before or after administration of *L. reuteri* or placebo. The effect of *L. reuteri* on persistence of water diarrhea is further presented in Table 4 and Figures 1a and 1b.

Table 4 Percent of Patients with Watery Diarrhea

Days of Therapy	¹	All Patients n = 40 Ratio ² (%)	<i>L. reuteri</i> Gp. n = 19 Ratio ² (%)	Placebo Gp. n = 21 Ratio ² (%)	p ³
Day-0		40/40 (100)	19/19 (100)	21/21 (100)	
5 Day-1		37/40 (93)	16/19 (84)	21/21 (100)	0.06
Day-2		22/40 (55)	5/19 (26)	17/21 (81)	0.0005
Day-3		13/40 (33)	2/19 (11)	11/21 (53)	0.004
Day-4		9/40 (23)	3/19 (16)	6/21 (24)	0.33
Day-5		5/40 (13)	2/19 (11)	3/21 (14)	0.71
10 Day-6		5/40 (13)	2/19 (11)	3/21 (14)	0.71

¹ Day 0, 1, 2, 3, 4, 5 and 6 correspond to 24 h prior to administration and 24, 48, 72, 96, 120, and 144 h post administration, respectively.

² With diarrhea/total.

³ Comparison of *L. reuteri* and Placebo groups.

15 By the second day of treatment watery diarrhea persisted in only 26% of *L. reuteri* recipients and as compared with 81% of placebo recipients. On the second day the frequency of watery stools decreased in the *L. reuteri* group; the means were 1.0 (SD 2.3) in the *L. reuteri* group and 2.5 (SD 2.3) in the placebo group (p=0.05) (Figure 1a). On the third day the mean frequency of watery stools was 0.5 (SD 1.9) in the *L. reuteri* group and 1.7 (SD 2.6) in the placebo group (p=0.12).

Fewer patients receiving *L. reuteri*, compared with those receiving placebo, had vomiting, starting from the second day of treatment (Table 5).

Table 5 Percent of Patients with Vomiting

Days of Therapy	1	All Patients n = 40 Ratio ² (%)	<i>L. reuteri</i> Gp. n = 19 Ratio ² (%)	Placebo Gp. n = 21 Ratio ² (%)	P ³
Day-0		23/40 (58)	7/19 (37)	16/21 (76)	0.01
5 Day-1		12/40 (30)	6/19 (32)	16/21 (29)	0.83
Day-2		4/40 (10)	0/19 (0)	4/21 (19)	0.04
Day-3		6/40 (15)	1/19 (5)	5/21 (24)	0.18
Day-4		4/40 (10)	0/19 (0)	4/21 (19)	0.04
Day-5		2/40 (5)	0/19 (0)	2/21 (10)	0.16
10 Day-6		2/40 (5)	0/19 (0)	2/21 (10)	0.16

¹ Day 0, 1, 2, 3, 4, 5 and 6 correspond to 24 h prior to administration and 24, 48, 72, 96, 120, and 144 h post administration, respectively.

² Vomiting/total.

³ χ^2 test (chi square test).

15 Figures 2a and 2b also illustrate the vomiting results. Vomiting practically stopped after the first day of therapy in the *L. reuteri* group, while in the placebo group it still lingered until the sixth day.

Administration of *L. reuteri* resulted in good colonization of the gastrointestinal tract (Figures 3-5 and Table 6).

Table 6 Faecal total lactobacilli and *L. reuteri* in patients treated with *L. reuteri* or placebo.

Clinical Evaluation	<i>L. reuteri</i> n=19 mean	Group SD	Placebo n=21 mean	Group SD	P ¹
5 <u>Total Lactobac.</u> (log CFU/g) Base line stool samples	2.71	1.57	3.08	1.69	0.41
10 48 hr stool	6.88	1.54	3.32	1.99	0.0001
Discharge stool	5.78	2.31	2.48	1.26	0.0025
15 <i>L. reuteri</i> (log CFU/g) Base line stool samples	1.86	0.06	1.85	0.00	0.29
48 hr stool	6.70	1.48	1.85	0.00	0.001
20 Discharge stool	5.45	2.57	1.85	0.00	0.008
<i>L. reuteri</i> (% Lactobac.) Base line stool samples	0.02	0.04	0.001	0.00	0.29
25 48 hr stool	78.7	33.9	0.01	0.00	0.0001
Discharge stool	71.5	48.6	0.01	0.00	0.0005

30 ¹ Student's t-test (p < 0.05-statistically significant difference)

As shown, a net increment of 10^7 CFU/g of *L. reuteri* in feces was observed after 48 hours of *L. reuteri* administration. Total lactobacilli CFUs also showed an increment of 10^5 CFU/g in feces 48 hours after the initial dose of *L. reuteri* (Table 6). *L. reuteri* accounted for more than 75% of total lactobacilli detected in stool samples. Total lactobacilli were low in the stools of placebo treated children, and *L. reuteri* was not detected in any of those stool samples. Throughout the study total faecal lactobacilli from placebo treated children were in the range of 10^1 to 10^5 CFU/g.

Fecal activities of the bacterial enzymes urease, β -glucuronidase (β -GLN), and β -glucosidase (β -GLS) were lower in the *L. reuteri* group than in the placebo group (Table 7).

Table 7 Fecal enzyme activities: β -GLN, β -GLS, and urease in *L. reuteri* and placebo groups (mmol \times min⁻¹ \times mg protein⁻¹)

	<i>L. reuteri</i> group n=12 median	IQR range	Placebo group n=9 median	IQR ² range	p ¹	
15	β -GLN-0	0.10	0-0.37	0.26	0.037-0.67	0.28
	β -GLN-2	0.27	0-0.1	0.17	0-1.16	0.54
	β -GLN-3	0.11	0-0.22 2 patients	0.29	0.01-1.27 5 patients	0.33
	β -GLS-0	0.47	0-1.29	0.39	0-2.32	0.72
	β -GLS-2	0.97	0-4.55	1.82	0.44-2.79	0.99
	β -GLS-3	0.52	0-1.04 2 patients	0.67	0.03-2.42 5 patients	0.56
20	Urease-0	0	0-2.09	1.23	0-23.66	0.22
	Urease-2	0.96	0-6.05	4.25	0-7.72	0.64
	Urease-3	0	0 2 patients	12.12	1.90-18.62 5 patients	0.12

¹ non parametric test (Mann-Whitney U)

² within a 95% confidence level

Rotavirus IgA class (circulating) antibodies were similar in the two study groups. On admission, the mean rotavirus IgA antibody levels in the *L. reuteri* group was 22.5 (SD 39.8) enzyme immunounits (EIU) and in the placebo group 7.99 (SD 21.8) EIUs ($p=0.163$). Four weeks later the mean rotavirus IgA antibody levels were 74.2 (SD 33.9) and 66.3 (SD 31.9) ($p=0.4705$) in the *L. reuteri* and in the placebo groups, respectively, indicating that diarrhea symptoms were decreased without need for an apparent increase in IgA levels, unlike results seen with *Lactobacillus GG*.

Early Administration

Administration of *L. reuteri* according to the invention is best as soon as there are diarrhea symptoms. Thus, when the treatment according to the invention as discussed above is administered on the first day when diarrhea symptoms are present, there is a substantial reduction in watery diarrhea and vomiting as compared to controls. This difference is most marked in rotavirus gastroenteritis.

Low Dosage Levels

Patients are given varying levels of *L. reuteri* from 10^7 to 10^{10} per day, which treatments provide similar decreases in diarrhea symptoms, with the rapidity of recovery being increased at the higher levels.

Form of Treatment with *L. reuteri*

In addition to use of a liquid suspension of *L. reuteri*, either freshly grown or as lyophilized cells resuspended in a chosen liquid, patients are given the same number of *L. reuteri* cells in a gelatin capsule, once a day. Particularly for mammals which already receive a pastelike nutritional supplement, the *L. reuteri* therapy may be included in the paste given to the mammal on at least a daily basis when diarrhea symptoms are noticed or when the mammal is likely to be susceptible to diarrhea (e.g., weaning). The same

results, reduced diarrhea symptoms, are observed with each of these types of formulation.

Multiple Daily Administration

In cases where the diarrhea symptoms are particularly severe at the beginning of therapy with the invention, administration of multiple aliquots of *L. reuteri* remedies the problem of the therapy being excreted from the body before having a chance to have its effect. Such instances include severe infant or child diarrhea.

Treatment of Other Mammals

The same diminution of diarrhea symptoms are observed in other mammalian systems with the therapy of the invention. Thus, administration of about 10^7 - 10^{10} cells per day to piglets prior to and/or at weaning reduces the incidence of rotavirus-induced diarrhea in pigs.

Preferred Embodiment of the Invention

Preferably the method of the invention of treating acute diarrhea, such as that due to rotavirus infections, which method is efficient and rapid in stopping dehydration of young patients, as well as in other mammals, includes determining that the patient has diarrhea or is imminently susceptible to diarrhea; selecting a strain of *Lactobacillus reuteri*; preparing at least one aliquot of lyophilized cells of the strain containing about 10^7 - 10^{10} cells for administration to the patient; and orally administering the at least one aliquot to the patient as soon as possible after diagnosis of diarrhea, and most preferably further includes a step selected from the group consisting of suspending the lyophilized cells in liquid, enclosing the lyophilized cells in a gelatin capsule, and enclosing the lyophilized cells in a moisture-impermeable container for storage until administered to the patient. The cells may be enclosed in a moisture-impermeable container for storage

until administered to the mammal. The cells may be suspended in a liquid such as water, dairy products, and fruit juices or may be placed in a gelatin capsule for administration to the mammal.

Industrial Applicability

- 5 The invention herein provides a method of treating acute diarrhea that is more effective and faster in stopping dehydration of young patients than earlier methods, and thus can provide savings of cost and time in health care systems.

While the invention has been described with reference to specific embodiments thereof, it will be appreciated that numerous variations, modifications, and embodiments
10 are possible, and accordingly, all such variations, modifications, and embodiments are to be regarded as being within the spirit and scope of the invention.

THE CLAIMSWhat Is Claimed Is:

1. A method of treating acute diarrhea that is efficient and rapid in stopping dehydration of young patients, comprising:
 - 5 a) determining that the patient has diarrhea or is imminently susceptible to diarrhea;
 - b) selecting a strain of *Lactobacillus reuteri*;
 - c) preparing at least one aliquot of cells of the strain containing about 10^7 - 10^{10} cells for administration to the patient; and
 - 10 d) orally administering the at least one aliquot to the patient as soon as possible after diagnosis of diarrhea.
2. The method of claim 1, wherein preparing the at least one aliquot comprises lyophilizing the cells, and further comprises a step selected from the group consisting of suspending the lyophilized cells in liquid, enclosing the lyophilized
15 cells in a gelatin capsule, and enclosing the lyophilized cells in a moisture-impermeable container for storage until administered to the patient.
3. A method of providing therapy to a mammal having diarrhea, comprising:
 - a) determining that the mammal has diarrhea or is imminently susceptible to diarrhea;
 - 20 b) selecting a strain of *Lactobacillus reuteri*;

- c) preparing at least one aliquot of cells of the strain containing about 10^7 - 10^{10} cells for administration to the mammal; and
 - d) orally administering the at least one aliquot to the mammal as soon as possible after diagnosis of diarrhea.
- 5 4. The method of claim 3, wherein about at least 10^8 cells are administered to the mammal once per day until the mammal is diarrhea-free.
5. The method of claim 3, wherein preparing said at least one aliquot comprises lyophilizing the cells.
6. The method of claim 5, wherein the lyophilized cells are suspended in a liquid
10 prior to administration.
7. The method of claim 6, wherein the liquid is selected from the group consisting of juices, dairy products and water.
8. The method of claim 5, further comprising enclosing the lyophilized cells in a gelatin capsule for administration to the mammal.
- 15 9. The method of claim 5, further comprising enclosing the lyophilized cells in a moisture-impermeable container for storage until administered to the mammal.

10. The method of claim 3, wherein the diarrhea is associated with rotavirus infection.
11. The method of claim 3, wherein the mammal is a human.
12. The method of claim 3, wherein the strain was isolated from the same type of
5 mammal as the mammal to which the therapy is being provided.
13. The method of claim 12, wherein the strain was isolated from a human.
14. The method of claim 13, wherein the strain was isolated from human breast milk.
15. A therapeutic preparation for reduction of diarrhea symptoms, comprising at least
about 10^7 viable cells of a strain of *Lactobacillus reuteri* in an aliquot for
10 administration to a mammal.
16. The therapeutic preparation of claim 15, wherein the cells are lyophilized and
packaged in a moisture-impermeable container.
17. The therapeutic preparation of claim 15, wherein the cells are suspended in a
liquid.
- 15 18. The therapeutic preparation of claim 17, wherein the liquid is selected from the
group consisting of water, dairy products, and fruit juices.

19. The therapeutic preparation of claim 15, wherein the cells are lyophilized and placed in a gelatin capsule for administration to the mammal.
20. The therapeutic preparation of claim 15, wherein the strain was isolated from a human, and the preparation is for human use.

1/4

FIGURE 1a.





FIGURE 1b.



2/4

FIGURE 2a.




FIGURE 2b.




FIGURE 3.






FIGURE 4.



4/4

FIGURE 5.



Applicant's or agent's file reference number	BIOA5074	International application No. PCT 15 07 0600
---	----------	---

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>4</u> , line <u>2</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville, MD 20852 United States of America	
Date of deposit December 7, 1995	Accession Number 55730
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Grows in LBS Medium (g/l: trypticase, 10; yeast extract, 5; KH_2PO_4 , 6l; ammonium citrate, 2; sodium acetate (tri-hydrate), 34; MgSO_4 (hepta-hydrate), 1.2; MnSO_4 (mono-hydrate), 0.13; FeSO_4 (hepta-hydrate), 0.06), adjusted to pH 5.5 with conc. HCl; 10 g glucose added after sterilization; regular, nonspring, Gram-positive rod; isolated from human breast milk	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p><i>J. Anton Smith</i></p> <p>Authorized officer</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	--

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/09626**A. CLASSIFICATION OF SUBJECT MATTER**IPC(6) : A01N 63/00; C12N 5/00
US CL : 424/93.4, 93.45; 435/254.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.4, 93.45; 435/254.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
APS, BIOSIS**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KANDLER et al. <i>Lactobacillus reuteri</i> sp. nov., a New Species of Heterofermentative Lactobacilli. Zbl. Bakt. Hyg., I. Abt. Orig. C 1. 1980. pages 264-269.	1-20

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later documents published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* Z*	document member of the same patent family
* O* documents referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

12 SEPTEMBER 1997

Date of mailing of the international search report

06 OCT 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer:

L. BLAINE LANKFORD

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196